STRO vs TXT · rev $62.0M vs P/E 19, rev $13.70B
Sutro Biopharma (STRO) versus Textron Inc (TXT) — a side-by-side from cached financials, not a winner call.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Textron Inc (TXT) is a aerospace & defense company listed on US.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
Latest reported TXT revenue for 2024-12-28 was $13.70B. Net income was $824.0M. Revenue was up 0.1% from 2023-12-30 to 2024-12-28. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
STRO currently screens at market cap $470.8M. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
Not investment advice. Open the STRO and TXT stock pages for the full models.
Not investment advice.